Obesity Drugs and GLP‑1 Therapies

The U.S. Food and Drug Administration has approved Wegovy HD, a new 7.2 mg injection of semaglutide from Novo Nordisk that triples the previous maximum 2.4 mg dose and is indicated for chronic weight management in adults with obesity or overweight plus at least one weight‑related condition. The decision, announced Thursday, is the fourth approval under the FDA’s National Priority Voucher pilot, which Commissioner Dr. Martin Makary says is meant to fast‑track products that address critical national health priorities such as obesity. Clinical data from the STEP UP trial showed patients on the higher dose lost an average of 20.7% of their body weight versus about 16% on the standard dose, with roughly one‑third losing 25% or more, while blood‑sugar reductions in people with type 2 diabetes were similar to the lower dose. The agency says the safety profile mirrors known GLP‑1 side effects like nausea, vomiting and abdominal pain but notes more frequent skin sensitivity and burning at higher doses, which it is investigating, and it warns the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Obesity and diabetes specialists say the new dose creates an evidence‑based escalation path for patients who plateau on 2.4 mg, though they caution it should be reserved for serious obesity management rather than cosmetic weight loss.